ALS publications
Papers and presentations from the ALS program.
All publications and presentations
- PerspectiveRestoring Regulatory Fairness and Reclaiming Biomedical Leadership: ALS, Rare Disease Regulation, and the Future of Regenerative MedicineJournal of the Academy of Public HealthView source
- PresentationCSF biomarker correlations with primary outcome in NurOwn® Phase 3 clinical trial2021 Annual NEALS MeetingView source
- Peer-reviewedEffects of MSC-NTF cells on T and B regulatory cell function in ALSAmyotrophic Lateral Sclerosis and Frontotemporal DegenerationView source
- PresentationMolecular characterization of VEGF secretion by MSC-NTF cells (NurOwn): therapeutic implications in ALS2019 Annual AAN MeetingView source
- PresentationA systematic review of enrichment strategies for current clinical trials in ALSInternational Symposium on ALS/MNDView source
- PresentationMicroRNA changes in the NurOwn Phase 2 ALS randomized clinical trial: relationship to neuroprotection and innate immunityAnnual NEALS ConferenceView source
- PresentationModulation of CSF miRNAs in ALS Phase 2 study participants treated with MSC-NTF cells (NurOwn)Annual AAN MeetingView source
- PresentationNurOwn Phase 2 ALS trial: ALSFRS-R improvement is reflected in subscale domainsAnnual AAN MeetingView source
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.